These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 24563075)

  • 1. Sorafenib in metastatic thyroid cancer: a systematic review.
    Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
    Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
    Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J; Handkiewicz-Junak D; Jarzab B
    Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery and development of sorafenib for the treatment of thyroid cancer.
    White PT; Cohen MS
    Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
    Dadu R; Devine C; Hernandez M; Waguespack SG; Busaidy NL; Hu MI; Jimenez C; Habra MA; Sellin RV; Ying AK; Cote GJ; Sherman SI; Cabanillas ME
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2086-94. PubMed ID: 24628550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to sorafenib treatment in advanced metastatic thyroid cancer.
    Pitoia F
    Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
    Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
    J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
    Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
    Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.